Skip to content
Menu

Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.

Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.

Read at benzinga.com